Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P) Abstract #99

Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.
Aim(s): To evaluate the expression of gene mutation and HIF-1 levels in P/P. In addition, these alterations as prognostic–predictive factors in P/P have been considered.
Materials and methods: A retrospective analysis of 30 P/P cases treated in our Istitute from 1999 to October 2009 was carried out. Nineteen patients had paragangliomas while the remaining 11 had pheochromocytomas. The main patient characteristics were: median age 49 yrs. (range 21-80); 16 males and 14 females; and the most common sites of disease were bone (36%), lymphnodes (30%), lung (16%), liver (16%). Twenty-six patients underwent resection of the primary tumor, while eight and 12 patients, respectively, were treated with chemotherapy and/or metabolic therapy. Additionally, in 12 patients the immunohistochemical evaluation of the SDHB mutation and the assessment of HIF-1 levels was carried out. The staining for SDHDB was optimized employing micro-slices of normal myocardial atrial muscle as positive control. To ensure antibody specificity, consecutive sections were incubated in absence of a primary antibody. The immunoreactivity was evaluated on a semiquantitative scale considering the extent (score 0-4) and the intensity (score 0-3) of staining. The product was used to obtain an immuno-staining score (total score 0-12).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta

To read results and conclusion, please login ...

Further abstracts you may be interested in

#480 Immunohistochemical (IHC) Overexpression of Succinate Dehydrogenase (SDHB) as Prognostic Factor in Sporadic Pheochromocytomas/Paragangliomas (P/P)
Introduction: Recently, gene mutations (SDH complex) involved in the pathogenesis of familial P/P have been discovered. These mutations are often associated with SDHB activity loss and activation of hypoxia signals.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
#2972 Characteristics and Management of Paragangliomas, 10 Years Experience
Introduction: Paraganglioma (PG) is a rare extra-adrenal neuroendocrine tumor, with common sites of presentation being abdomen, and head and neck region. The majority of PGs appear to be sporadic. However, almost half of cases are associated with an inherited syndrome. The highest malignancy rates are seen in paragangliomas (PGs) associated with SDHB mutations, which are usually abdominal and secretory.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Emilia Sardo
#581 Loss of Succinate Dehydrogenase (SDHB) Expression in Midgut Carcinoids as Prognostic Factor: a New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of SDH complex have been involved in the pathogenesis of cancer cells. These mutations are often associated with loss of activity of SDH subunity B and overexpression of HIF-1a, which play a central role in angiogenesis.
Conference:
Category: Basic
Presenting Author: Dr. Massimo Milione
#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Fabrice Viol
Authors: Viol F, Sipos B, Amin T, Fahl M, ...
#246 SDHB Loss Predicts Malignancy in Pheochromocytomas/Sympathethic Paragangliomas, but Not Through Hypoxia Signalling
Introduction: To date there is no reliable histopathological marker of malignancy for pheochromocytomas/sympathetic paragangliomas (PCC/PGL). It is well-known that PCC/PGL in the hereditary context of an SDHB germline mutation very often metastasize. The immunohistochemical loss of SDHB expression was recently shown to be a surrogate marker for the presence of an SDH germline mutation in PCC/PGL. SDHB loss is supposed to be tumorigenic via activation of hypoxia signals.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Anja M Schmitt